Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled Study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled Study ; volume:13 ; number:3 ; day:17 ; month:1 ; year:2023 ; pages:751-768 ; date:3.2023
Dermatology and therapy ; 13, Heft 3 (17.1.2023), 751-768, 3.2023
- Creator
-
Asahina, Akihiko
Okubo, Yukari
Morita, Akimichi
Tada, Yayoi
Igarashi, Atsuyuki
Langley, Richard G.
Deherder, Delphine
Matano, Mizuho
Vanvoorden, Veerle
Wang, Maggie
Ohtsuki, Mamitaro
Nakagawa, Hidemi
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s13555-022-00883-y
- URN
-
urn:nbn:de:101:1-2024040316280778650478
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:55 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Asahina, Akihiko
- Okubo, Yukari
- Morita, Akimichi
- Tada, Yayoi
- Igarashi, Atsuyuki
- Langley, Richard G.
- Deherder, Delphine
- Matano, Mizuho
- Vanvoorden, Veerle
- Wang, Maggie
- Ohtsuki, Mamitaro
- Nakagawa, Hidemi
- SpringerLink (Online service)
Other Objects (12)
Ustekinumab : Behandlung der Plaque-Psoriasis und aktiven Psoriasis-Arthritis
Ustekinumab : bei mittelschwerer bis schwerer Plaque-Psoriasis : bei aktiver Psoriasis-Arthritis
Bulky Condyloma Acuminata following Ustekinumab Treatment for Plaque Psoriasis: A Case Report
Urticarial Reaction to Ustekinumab During the Treatment of Plaque Psoriasis in a Hepatitis C-Positive Patient
Inhibition of Receptor-Interacting Protein Kinase 1 in Chronic Plaque Psoriasis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
Dermatology Life Quality Index in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab or Ustekinumab
Psoriasis, Psoriasis-Arthritis und Morbus Crohn : Ustekinumab zeigt langfristige Wirksamkeit und gutes Safety-Profil
Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)
Plaque-Psoriasis – Ponesimod zeigt Wirksamkeit
Retrospektive Untersuchung der Therapieadhärenz von Secukinumab, Ustekinumab und Certolizumab pegol im Rahmen der Routinebehandlung bei Patienten mit mittelschwerer bis schwerer Plaque-Psoriasis oder/und Psoriasis-Arthritis
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
Ustekinumab (Stelara) : Ustekinumab bei besonderen CED-Situationen
Ustekinumab : Behandlung der Plaque-Psoriasis und aktiven Psoriasis-Arthritis
Ustekinumab : bei mittelschwerer bis schwerer Plaque-Psoriasis : bei aktiver Psoriasis-Arthritis
Bulky Condyloma Acuminata following Ustekinumab Treatment for Plaque Psoriasis: A Case Report
Urticarial Reaction to Ustekinumab During the Treatment of Plaque Psoriasis in a Hepatitis C-Positive Patient
Inhibition of Receptor-Interacting Protein Kinase 1 in Chronic Plaque Psoriasis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
Dermatology Life Quality Index in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab or Ustekinumab
Psoriasis, Psoriasis-Arthritis und Morbus Crohn : Ustekinumab zeigt langfristige Wirksamkeit und gutes Safety-Profil
Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)
Plaque-Psoriasis – Ponesimod zeigt Wirksamkeit
Retrospektive Untersuchung der Therapieadhärenz von Secukinumab, Ustekinumab und Certolizumab pegol im Rahmen der Routinebehandlung bei Patienten mit mittelschwerer bis schwerer Plaque-Psoriasis oder/und Psoriasis-Arthritis
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
Ustekinumab (Stelara) : Ustekinumab bei besonderen CED-Situationen
Ustekinumab : Behandlung der Plaque-Psoriasis und aktiven Psoriasis-Arthritis
Ustekinumab : bei mittelschwerer bis schwerer Plaque-Psoriasis : bei aktiver Psoriasis-Arthritis
Bulky Condyloma Acuminata following Ustekinumab Treatment for Plaque Psoriasis: A Case Report
Urticarial Reaction to Ustekinumab During the Treatment of Plaque Psoriasis in a Hepatitis C-Positive Patient
Inhibition of Receptor-Interacting Protein Kinase 1 in Chronic Plaque Psoriasis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
Dermatology Life Quality Index in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab or Ustekinumab
Psoriasis, Psoriasis-Arthritis und Morbus Crohn : Ustekinumab zeigt langfristige Wirksamkeit und gutes Safety-Profil
Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)
Plaque-Psoriasis – Ponesimod zeigt Wirksamkeit
Retrospektive Untersuchung der Therapieadhärenz von Secukinumab, Ustekinumab und Certolizumab pegol im Rahmen der Routinebehandlung bei Patienten mit mittelschwerer bis schwerer Plaque-Psoriasis oder/und Psoriasis-Arthritis
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial